Has a solid pipeline of products that should be advancing into phase 3 stage of FDA approval and beyond through the next 12 to 36 months. Most notable of all its products currently in phase 2 stage of development, is the drug Convivia. It is the only… More
Fools bullish on RPTP
are also bullish on:
Raptor has sneakily crossed back above my red thumb threshold in the absence of new positive catalysts. The DR Cysteamine NDA won't be filed until Q1 2012 which means we won't be seeing any revenue numbers until at least 2013. I think the traders who… More
Fools bearish on RPTP
are also bearish on: